{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-083326","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2026-07-14T11:00:58+00:00","discovered_at":"2026-07-14T11:05:01.278620+00:00","generated_at":"2026-07-14T11:05:10.190447+00:00","sec_items":["1.01","2.05","5.01","5.02","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"NextCure to reverse merge with Avere; Avere holders get ~98% of combined co; $320M PIPE","bullets":["NextCure (NXTC) to acquire Avere Therapeutics via reverse merger; Avere stockholders will own ~98.11% of combined company; NextCure stockholders ~1.89%.","Concurrent $320M private placement from institutional investors into Avere; condition of at least $150M proceeds at close.","NextCure to reduce workforce by substantial majority; expects ~$1.9M one-time charges in Q3 2026.","NextCure halts new patient enrollment in SIM0505 ADC study in US; opts out of cost-sharing for LNCB74 ADC; not due to safety/efficacy.","Pre-merger NextCure stockholders to receive CVRs entitling them to 90% of proceeds from future monetization of legacy assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-083326","json":"https://secwatch.observer/filing/0001104659-26-083326.json","markdown":"https://secwatch.observer/filing/0001104659-26-083326.md","text":"https://secwatch.observer/filing/0001104659-26-083326.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926083326/0001104659-26-083326-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926083326/tm2620428d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-14T11:05:10.190447+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}